Dermatology Times' Weekly Crossword: July 28, 2025

Welcome to Dermatology Times' Weekly Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

6. Autoimmune disease reviewed in a “Rheum With a View” session focusing on cutaneous manifestations at DERM 2025.

8. IL‑23 inhibitor with positive phase 3 results reported for psoriatic arthritis.

9. Biologic that Jacob Thyssen, PhD, highlighted as promising for hard‑to‑treat hand eczema.

11. Investigational psoriasis agent with positive phase 3 results in high‑impact areas presented at DERM 2025.

12. Castle Biosciences’ melanoma test that earned FDA Breakthrough Device designation for risk stratification.

14. (Abbreviation)Lymphoma in which pruritus severity correlated with quality of life in this week’s Journal Digest.

15. PDE4 inhibitor cream being studied for safety and efficacy in infants with atopic dermatitis in the INTEGUMENT-INFANT trial.

16. Biologic shown effective for genital and scalp psoriasis in the UnlIMMited poster at DERM 2025.

Down

1. TYK2 inhibitor with an FDA‑accepted sNDA for treating active psoriatic arthritis.

2. (Abbreviation) “Forever chemicals” Michelle Hure, MD, warned may pose clinical concerns in dermatology products.

3. BTK inhibitor demonstrating swift CSU activity score reductions at Elevate‑Derm Summer.

4. Aesthetic agents whose broader impact was explored using patient‑reported outcomes by Steven Dayan, MD.

5. Cancer type where gene expression profiling is transforming management of recurrence risk and treatment decisions.

7. Pan-JAK inhibitor cream newly FDA‑approved as the first approved therapy in the US for chronic hand eczema in adults.

10. testing (2 words) Diagnostic step Walter Liszewski, MD, highlighted for tailoring atopic dermatitis care.

13. (Abbreviation) Global health body whose new resolution on skin diseases aims to close care gaps worldwide.

For answers to this week's puzzle, check out next week's edition of the Dermatology Times Weekly Crossword.

Answers from our July 20, 2025 puzzle: [Across: 5 - SPFVault, 7 - retinoid, 11 - spesolimab, 13 - pregnancy, 14 - niacinamide, 15 - acne, 16 - melanoma, 17 - CHE, 18 - art, 19 - deuruxolitinib, 20 - eczema; Down: 1 - vitiligo, 2 - hidradenitis, 3 - laser, 4 - guidelines, 6 - Treg, 8 - trifarotene, 9 - abrocitinib, 10 - dupilumab, 12 - alopecia, 21 - CSU]